$107B in 2+ years? Pfiz­er’s Covid-19 vac­cine may re­de­fine ‘megablock­buster’ by 2022 — an­a­lyst

If both its BioN­Tech-part­nered Covid-19 vac­cine and in-house an­tivi­ral live up to their full promis­es, Pfiz­er may be sit­ting on a $100 bil­lion gold­mine in 2022.

That’s ac­cord­ing to SVB Leerink an­a­lyst Ge­of­frey Porges, who re­leased his lat­est fore­cast ear­ly Tues­day com­plete with a lengthy break­down of all the in­tri­cate fac­tors go­ing in­to his cal­cu­la­tion. Bot­tom line: uni­ver­sal boost­ing and pe­di­atric rec­om­men­da­tions will shore up glob­al Covid vac­cine sales to $59 bil­lion in 2021 and $48 bil­lion in 2022, or $107 bil­lion in cu­mu­la­tive sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER